GeoVax Labs, Inc. Warrants
GOVXW
About: Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
Employees: 17
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
250% more funds holding
Funds holding: 2 [Q1] → 7 (+5) [Q2]
8.5% more ownership
Funds ownership: 0% [Q1] → 8.5% (+8.5%) [Q2]
26% less capital invested
Capital invested by funds: $6.81K [Q1] → $5.01K (-$1.8K) [Q2]
Financial journalist opinion
We haven’t received any recent news articles for GOVXW